RXMD has double-bottom key support lined up with a major MACD buy signal after breaking above its recent downtrend line in yesterday's action. This is a Coronavirus play at the leading edge in both telehealth and home pharmacy delivery.
• Telehealth regulations have been dropped to allow it to brace our healthcare system against exponential COVID-19 case growth. • RXMD is currently priced at 0.5x trailing sales, which is extremely cheap, even for a pharmacy play. • This is especially true given that it just posted 56% top-line growth and is moving toward the likely launch of a telemedicine platform. • RXMD is moving toward a NASDAQ or NYSE uplisting.